Business
MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics
MEDI&GENE, a biopharmaceutical company developing therapeutics for metabolic diseases, announced today that it has entered into a Catalyze agreement with Eli Lilly and Company (Lilly) to advance a next-generation therapeutic for obesity.
About this update from Eli Lilly And Company
[{"type":"text","content":"SEOUL, South Korea, Dec. 17, 2025 /PRNewswire/ -- MEDI&GENE, a biopharmaceutical company developing therapeutics for metabolic diseases, announced today that it has entered into a Catalyze agreement with Eli Lilly and Company (Lilly) to advance a next-generation therapeutic for obesity.","length":326,"tagName":"p"},{"type":"image","alt":"MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics","displaySize":"","headline":null,"caption":"MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":67,"url":"https://media.zenfs.com/en/prnewswire.com/44ad7592501561e607f23cc664e887b9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2KVDA8UPIComQdmZN0ebiw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/44ad7592501561e607f23cc664e887b9","width":400,"height":67}},"href":"https://mma.prnewswire.com/media/2847314/medi_gene__signature_A_re_size_01.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"MEDI&GENE's discovery platform is designed to unlock novel therapeutic pathways that have the potential to sustain long-term weight maintenance, lean mass maintenance, and durability of desired metabolic effects.","length":225,"tagName":"p"},{"type":"text","content":"Under the agreement, Lilly ExploR&D will bring Lilly's expertise in molecule engineering and development to a MEDI&GENE asset, with the goal to advance the program to clinical trial readiness. Lilly ExploR&D is part of the Lilly Catalyze360 suite of offerings designed to empower biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities.","length":440,"tagName":"p"},{"type":"text","content":""We are excited to work with Lilly to advance a next-generation obesity drug candidate. We believe this collaboration will accelerate clinical development and help bring differentiated solutions to patients with obesity," said Min-Jeong Shin, CEO of MEDI&GENE.","length":274,"tagName":"p"},{"type":"text","content":"Founded in 2021, MEDI&GENE has established a discovery engine centered on metaboli...